Together, these reports demonstrate that inhibition of TGF-β signaling via pharmacological modulation may reduce cardiac fibrosis, improve heart function and decrease cardiomyopathy in a wide variety of preclinical models. This evidence concerns the gene TGFB1 and cardiomyopathy.